key: cord-0741774-tdrnhhnt authors: Zhang, Songzi; Chen, Hongbin; Yue, Dayong; Blackwell, Timothy S.; Lv, Changjun; Song, Xiaodong title: Long non‐coding RNAs: Promising new targets in pulmonary fibrosis date: 2021-02-11 journal: J Gene Med DOI: 10.1002/jgm.3318 sha: 3fb516a4dca0bcc60eec4769b28094d31025dc4e doc_id: 741774 cord_uid: tdrnhhnt Pulmonary fibrosis is characterized by progressive and irreversible scarring in the lungs with poor prognosis and treatment. It is caused by various factors, including environmental and occupational exposures, and some rheumatic immune diseases. Even the rapid global spread of the COVID‐19 pandemic can also cause pulmonary fibrosis with a high probability. Functions attributed to long non‐coding RNAs (lncRNAs) make them highly attractive diagnostic and therapeutic targets in fibroproliferative diseases. Therefore, an understanding of the specific mechanisms by which lncRNAs regulate pulmonary fibrotic pathogenesis is urgently needed to identify new possibilities for therapy. In this review, we focus on the molecular mechanisms and implications of lncRNAs targeted protein‐coding and non‐coding genes during pulmonary fibrogenesis, and systematically analyze the communication of lncRNAs with various types of RNAs, including microRNA, circular RNA and mRNA. Finally, we propose the potential approach of lncRNA‐based diagnosis and therapy for pulmonary fibrosis. We hope that understanding these interactions between protein‐coding and non‐coding genes will contribute to the development of lncRNA‐based clinical applications for pulmonary fibrosis. Tissue fibrosis is a hallmark of chronic diseases in many organs, disturbing their architecture and resulting in dysfunction and failure. 1, 2 Almost 45% of deaths are attributed to chronic fibroproliferative diseases, including pulmonary fibrosis. 3 In addition to idiopathic pulmonary fibrosis (IPF) of unknown cause, progressive pulmonary fibrosis is the result of various factors, including environmental and occupational exposure, such as asbestos, mineral dust and radiation damage. Some rheumatic immune diseases, including systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome and dermatomyositis, can be accompanied by pulmonary fibrosis. Sudden public health events, such as the severe acute respiratory syndrome coronavirus, H5N1-virus and the rapid global spread of the COVID-19 pandemic, can also cause pulmonary fibrosis in many patients. 4, 5 At present, the longterm pulmonary consequences of COVID-19 remain speculative and should not be assumed without appropriate prospective study. However, from the data of previous coronavirus infections such as severe acute respiratory syndrome and Middle East respiratory syndrome, it is suggested that there could be substantial fibrotic consequences Songzi Zhang and Hongbin Chen contributed equally to this work. following the COVID-19 pandemic, and that even rare complications will have major health effects at the population level. 6, 7 Despite significant progress in understanding disease pathogenesis, treatments for lung fibrosis are limited. 8, 9 Two drugs, namely nintedanib and pirfenidone, are currently approved by the Food and Drug Administration for IPF treatment. Nintedanib is an intracellular tyrosine kinase inhibitor and pirfenidone is an anti-fibrotic molecule that appears to work by reducing the proliferation and differentiation of fibroblasts. However, these drugs do not improve symptoms and are poorly tolerated. 10, 11 Lung transplantation is the only treatment to improve life quality and the survival of pulmonary fibrosis patients. 12 However, only a small proportion of patients can benefit from lung transplantation given that the demand outstrips the supply for organ transplants and immune rejection is still a serious challenge. As a result, a complete understanding of the molecular mechanisms implicated in pulmonary fibrosis pathogensis is urgently required to enable the development of new treatments. Long non-coding RNA (lncRNA) is defined as a regulatory noncoding RNA of more than 200 nucleotides, including intergenic transcripts and enhancer RNA with sense or antisense orientation. 13, 14 lncRNAs regulate numerous biological processes through different mechanisms in the nucleus and cytoplasm and are highly cell/ tissue-specific. 15, 16 In this review, we focus on the molecular mechanisms and implications of lncRNAs during pulmonary fibrogenesis. Meanwhile, how lncRNAs cross-talk with various types of RNAs, including microRNA (miRNA), circular RNA (circRNA) and mRNA, is also discussed. Finally, we propose the potential approach of lncRNA-based diagnosis and therapy for pulmonary fibrosis. The act of transcription or the DNA element within the lncRNA locus are more likely to be the source of regulatory activity than the actual lncRNA itself. 17, 18 Using a genome-scale CRISPR-Cas9 activation screen of 10,000 lncRNA transcriptional start sites, Joung et al. 19 reported that the majority of candidate loci appear to regulate nearby genes. In addition, lncRNA can form a RNA-protein complex with its binding protein to exert a positive or negative function. 20 In pulmonary fibrosis, lncRNAs participate in the pathologic development of fibrosis by distinct mechanisms in different cell types, such as epithelial cells, fibroblasts and macrophages, etc. The initial phase of pulmonary fibrosis is usually considered to be a consequence of repetitive micro-injuries to the alveolar epithelium, leading to changes in the cell microenvironment, fibroblast activation and deposition of matrix components. 21, 22 Gokey et al. 23 have identified 21 altered lncRNAs using single-cell RNA sequencing and MEG3 was found to be the most increased lncRNA in IPF epithelial cells. lncMEG3 positively correlates with basal cell markers TP63, KRT5, KRT17, KRT14 and ITGB4, and negatively correlates with normal alveolar type II cell markers ABCA3, SFTPC and SFTPB. Further studies demonstrated that the lncMEG3 influences abnormal epithelial cell differentiation and increased epithelial cell migration by regulating numerous genes, including TP63, STAT3, KRT14, YAP1, AXL, TP53, EZH2 and transforming growth factor (TGF)β. 23 However, the initial molecular mechanism and the close communication between lung epithelial cells and other type cells for fibrogenesis still remains unclear. Recently, Fukushima et al. 24 demonstrated that alveolar epithelium cells apoptosis is sufficient to cause fibrosis by dysregulating the expression of nuclear exosome targeting complex component Rbm7-lncNEAT1 axis, triggering the epithelium apoptosis in Rbm7-deficient mice, bleomycin-induced fibrosis mice, nonhematopoietic (CD45 − ) cells and RBM7 −/− HEK293 cells. Further mechanistic studies revealed that highly expressed Rbm7 induces the degradation of lncNEAT1 paraspeckles and the mislocalization of BRCA1 that disperses from lncNEAT1 paraspekles, leading to impaired DNA repair and triggering apoptosis. The dying alveolar epithelium releases chemokines that recruit atypical monocytes to drive lung fibrosis. 24 On the whole, injured alveolar epithelium cells cause changes in not only TGFβ and chemokines, but also other microenvironment factors, such as hypoxia and reactive oxygen species (ROS). The role of lncRNA telomeric repeat-containing RNA (TERRA) was also investigated in H 2 O 2 -treated alveolar epithelial cells, bleomycintreated mice lung fibrosis and IPF patients. 25 Functionally, lncTERRA accelerates the fibrotic process by promoting alveolar epithelium apoptosis. Mechanistically, lncTERRA forms a stable complex with the telomere repeat factor TRF2 and telomere DNA repeats to accelerate IPF pathogenesis through telomeric and mitochondrial pathways. During lung fibrogenesis, lncTERRA prevents telomere elongation by inhibiting telomerase activity and reverse transcriptase, and this condition inhibits cell cycle progression. Proliferating cell nuclear antigen, cyclin D1 and cyclin E are the regulatory factors of telomerase activity. RNA interference on lncTERRA enhances the expression of these factors, and this improvement promotes cell growth. The mitochondrion is also identified as the lncTERRA regulator of the IPF process. RNA interference on lncTERRA can ameliorate the functions of mitochondria by improving mitochondrial morphology, the electron transport chain and mitochondrial membrane potential. The findings demonstrate that lncTERRA contributes to fibrotic process by causing telomere attrition and mitochondrial dysfunction, in which mitochondria-associated genes (Bcl-2 family, cytochrome c, caspase-9 and caspase-3), oxidative stress-associated genes or products (ROS, superoxide dismutase and catalase) and senescence regulatory genes (P53 and p53-upregulated modulator of apoptosis) are all involved and play different important roles. 25 Targets and therapeutic interventions with respect to the dysfunction of organelles have been developed. Nandrolone decanoate-targeted abnormal telomere shortening is currently in a clinical trial and targets several diseases, including IPF (NCT02055456). 2 MitoQ, which is a mitochondrially targeted antioxidant, is currently used in middle-aged and older adults (NCT02597023). 26 lncRNAs provide new strategies for intervening in the functioning of these organelles. lncAP003419.16 is highly expressed in TGFβ1-treated alveolar epithelial cells and IPF patients, 27 in which lncAP003419.16 facilitates pulmonary fibrosis via the mammalian target of rapamycin (mTOR) signaling pathway dependent on its adjacent gene ribosomal protein S6 kinase B-2 (RPS6KB2). Given that the mTOR signaling pathway and RPS6KB2 are involved in the process of aging and IPF, 28, 29 it was proposed that lncAP003419.16 may predict an increased risk of agingassociated IPF. Ageing is a crucial risk factor for pulmonary fibrosis independent of genetics and environment because most patients are older than 60 years. 30, 31 Numerous lncRNAs influence the molecular processes that underlie age-associated phenotypes. 32, 33 However, additional credible evidence is needed to confirm that lncAP003419.16 predicts the risk of IPF because of the limited number of 20 patients investigated so far. In addition, the A549 cell model is easily questioned. A549 is often regarded as a normal representative of type II human alveolar epithelial cells, 34, 35 although it is still a human lung adenocarcinoma cancer cell line. The characterization of fibrosis and cancer, such as the metabolism process and specific markers, is different. Other lncRNAs in epithelial cells are lncRNAs-uc.77 and 2700086A05Rik, which directly target zinc finger E-box-binding homeobox 2 and homeobox protein Hox-A3 to promote paraquatinduced pulmonary fibrosis by enhancing epithelial-mesenchymal transition (EMT) with increased α-smooth muscle actin (SMA) and vimentin and reduced E-cadherin. 36 Overall, because the current strategy for treating fibrosis is mainly focused on fibroblasts, these lncRNAs, as initial mediators in fibrotic pathogenesis, provide promising new targets in epithelial cells for the early treatment of fibrosis. The fundamental pathogenic hallmarks of pulmonary fibrosis are uncontrolled proliferation and the high migration of activated fibroblasts. In pulmonary fibrosis, Song et al. 37 There are many reasons for this, including the detection method (RNA-sequencing or microarray), sample selection (cell type, rat, mice, patient blood or tissue) and the development of detection technology, and so on. These lncRNAs are roughly classified as sense-exon-overlap, sense-intron-overlap, antisense-exon-overlap, antisense-intron-overlap, bidirectional and intergenic according to their positions in genes. Among these lncRNAs, 15 lncRNAs show 90% sequence similarity to exons of protein-coding genes spread across different chromosomes. 37 The working mechanism of lncITPF is further elucidated in fibroblasts from IPF patients and human embryonic lung fibroblasts. 39 lncITPF is transcribed from the tenth intron to the eleventh exon of its host gene integrin b-like 1 (ITGBL1) and upregulated in the nucleus, which indicates that lncITPF regulates ITGBL1 transcription. ITGBL1 contains 10 repeats of epidermal growth factor-like domain and encodes a β integrin-related protein TIED; its high expression facilitates metastasis and invasion and correlates with poor survival in cancer patients. 40 In pulmonary fibrosis, high ITGBL1 expression increases the fibrotic markers, such as a-SMA, vimentin and collagen, and promotes myofibroblast proliferation and migration, thus resulting in fibrogenesis. The pro-fibrotic role of lncITPF depends on ITGBL1 by enhancing H3 and H4 histone acetylation of the ITGBL1 promoter, in which lncITPF forms an RNA-protein complex with its direct binding protein Certain studies have confirmed an incidence of lung cancer of 4.8%-48% and, without pulmonary fibrosis, of 2.0%-6.4% 43 ; thus, IPF has been considered a precancerous condition or another form of cancer. 44, 45 p53 is an important tumor gene because approximately 50% mutated p53 gene appear in tumors. 46 Recently, lncRNA cyclin-dependent kinase inhibitor-2B-antisense RNA 1 (CDKN2B-AS1) in IPF patients was reported to predict lung cancer by regulating the p53-signaling pathway. lncCDKN2B-AS1 is reduced in the peripheral blood of IPF patients, and its neighboring gene CDKN2A is decreased simultaneously. 47 Silicosis is a progressive pulmonary fibrosis and is initiated via the phagocytosis of silica particles by alveolar macrophages. An alteration profile of lncRNAs has been investigated in lung tissues of silicainduced rats. 55 Upregulated lncRNA LOC103691771 in the silicotic rat lung was further confirmed to activate macrophages and promote fibroblast differentiation via regulation of the TGFβ1-Smad2/3 signaling pathway. 56 Thus, investigations of lncRNA in macrophages will modulate the alveolar microenvironment, which will ameliorate pulmonary fibrosis. EndMT and the upregulated lncRNA Gm16410 was further investigated and it was found that lncRNA Gm16410 mediates PM2.5-induced EndMT by regulating the TGF-β1/Smad3/p-Smad3 pathway, which highlights the potential of lncRNAs to promote pulmonary fibrosis under environmental pollution. 57 The above-mentioned lncRNAs, located in various cells that directly target protein-coding genes to regulate pulmonary fibrosis, are listed in Table 1 . High-throughput technologies reveal that less than 2% of the human genome encodes protein, with the majority of the genome comprising ncRNAs that are not translated into proteins. 58 Among these ncRNAs, regulatory ncRNAs including miRNA, lncRNA and circRNA can function as vital regulators of gene expression. 65 this regulatory mode has been reported in many diseases. 66 Huang et al. 67 The hypoxia-induced H19/YB-1 cascade modulates cardiac remodeling after infarction and may be a prognostic marker for cancer. 74, 75 Several studies have shown that H19 is highly upregulated in pulmonary fibrosis in vivo and in vitro. Additional detailed information regarding the above-mentioned lncRNAs that regulate pulmonary fibrosis through miRNAs is summarized in Table 2 . CircRNA is a closed-loop structure generated by pre-mRNA back 102 Astragaloside IV treatment increases lncsirt1 AS and lncsirt1 F I G U R E 1 Molecular mechanisms of lncRNAs and lncRNA-based clinical applications in pulmonary fibrosis. Aging, environmental exposure or genetic predisposition to alveolar epithelial cell results in the release of pro-fibrotic factors, such as growth factors, cytokines, chemokines and matrix metalloproteinases, which promote abnormal and persistent fibroblast activation and remodeling, macrophage M1/M2 polarization classification, and endothelial-mesenchymal transition. Meanwhile, many abnormal organelles, including telomere attrition, endoplasmic reticulum stress and mitochondrial dysfunction, are also involved in fibrogenesis. lncRNAs participate in these abnormal biological processes in the nucleus or cytoplasm via diverse mechanisms and thus regulate numerous signaling pathways in different cell types to control pulmonary fibrogenesis. (1) The images present the various methodologies for lncRNA as the diagnostic marker. (2) lncRNA-based therapeutic strategies are proposed depending on their different regulatory patterns AS and is validated to enhance the stability of sirt1 and increase sirt1 expression, thereby preventing IPF. 103 Certainly, lncRNA-based clinical application still has some challenges. In some cases, several lncRNAs cover the intronic and exonic sequences of their host genes, which suggests the possibility of lncRNA-based pharmacological approaches producing off-target effects. 105 In addition, a few lncRNAs actually encode small proteins. 17, 106 Individual lncRNA can also act as both a protein-coding gene and an ncRNA. 107 Nevertheless, the protein-coding potential of lncRNA in pulmonary fibrosis is not still documented. Despite potential issues, the spatial-, temporal-and tissue-specific expression patterns of lncRNAs suggest that this is a promising area for new targets in pulmonary fibrosis. Potential lncRNA-based clinical applications are listed in Figure 1 . The authors declare that they have no conflicts of interest. The datasets used and analysed during the current study are available from the corresponding author upon reasonable request. Mechanisms of fibrosis: therapeutic translation for fibrotic disease Targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients SARS: prognosis, outcome and sequelae Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guide line Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner society white paper A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis Lung transplantation for idiopathic pulmonary fibrosis Functional classification and experimental dissection of long noncoding Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis Developmental dynamics of lncRNAs across mammalian organs and species Distinct processing of lncRNAs contributes to non-conserved functions in stem cells Transcription of the non-coding RNA upperhand controls Hand2 expression and heart development Local regulation of gene expression by lncRNA promoters, transcription and splicing Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood Protein complex scaffolding predicted as a prevalent function of long non-coding RNAs Idiopathic pulmonary fibrosis Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model MEG3 is increased in idiopathic pulmonary fibrosis and regulates epithelial cell differentiation Dysregulated expression of the nuclear exosome targeting complex component Rbm7 in nonhematopoietic cells licenses the development of fibrosis Regulation of TERRA on telomeric and mitochondrial functions in IPF pathogenesis The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in mice Upregulation of long noncoding RNA AP003419.16 predicts high risk of aging-associated idiopathic pulmonary fibrosis Ribosomal protein S6 kinase 1 signaling regulates mammalian life span Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients The hallmarks of aging Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs Long noncoding RNAs (lncRNAs) and the molecular hallmarks of aging LncRNAs regulatory networks in cellular senescence Direct GR binding sites potentiate clusters of TF binding across the human genome Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis Integrated long non-coding RNA analyses identify novel regulators of epithelial-mesenchymal transition in the mouse model of pulmonary fibrosis Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary fibrosis Differential expression of long noncoding RNAs in bleomycin-induced lung fibrosis lncITPF promotes pulmonary fibrosis by targeting hnRNP-L depending on its host gene ITGBL1 Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer Integrated analysis of a gene correlation network identifies critical regulation of fibrosis by lncRNAs and TFs in idiopathic pulmonary fibrosis Crosstalk of mRNA, miRNA, lncRNA, and circRNA and their regulatory pattern in pulmonary fibrosis Cumulative incidence of and predictive factors for lung cancer in IPF Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology Astaxanthin prevents pulmonary fibrosis by promoting myofibroblast apoptosis dependent on Drp1-mediated mitochondrial fission The emerging p53 gene family Low expression of long noncoding RNA CDKN2B-AS1 in patients with idiopathic pulmonary fibrosis predicts lung cancer by regulating the p53-signaling pathway Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest A cell cycle regulator potentially involved in genesis of many tumor types ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report Protective and pathogenic functions of macrophage subsets Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis Long noncoding RNA Malat1 regulates differential activation of macrophages and response to lung injury Profiling long non-coding RNA changes in silica-induced pulmonary fibrosis in rat Differential expression of lncRNAs during silicosis and the role of LOC103691771 in myofibroblast differentiation induced by TGF-β1 LncRNA Gm16410 regulates PM2.5-induced lung endothelial-mesenchymal transition via the TGF-β1/Smad3/ p-Smad3 pathway Landscape of transcription in human cells Inhibition and role of let-7d in idiopathic pulmonary fibrosis MicroRNA-29c prevents pulmonary fibrosis by regulating epithelial cell renewal and apoptosis Insights into circular RNA biology Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues The long noncoding RNA DNM3OS is a reservoir of fibromiRs with major functions in lung fibroblast response to TGF-β and pulmonary fibrosis A long noncoding RNA links TGF-β signaling in lung fibrosis Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA Interaction of long noncoding RNAs and microRNAs in the pathogenesis of idiopathic pulmonary fibrosis Comprehensive analysis of lncRNA-associated competing endogenous RNA network and immune infiltration in idiopathic pulmonary fibrosis MLK3 is part of a feedback mechanism that regulates different cellular responses to reactive oxygen species A novel lnc-PCF promotes the proliferation of TGF-β1-activated epithelial cells by targeting miR-344a-5p to regulate map 3k11 in pulmonary fibrosis lncRNA PFAR promotes lung fibroblast activation and fibrosis by targeting miR-138 to regulate the YAP1-twist axis lncRNA PFAL promotes lung fibrosis through CTGF by competitively binding miR-18a Inhibition of lncRNA PFRL prevents pulmonary fibrosis by disrupting the miR-26a/smad2 loop Hypoxia-induced H19/YB-1 cascade modulates cardiac remodeling after infarction Identification of lncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer Knockdown of long noncoding RNA H19 represses the progress of pulmonary fibrosis through the transforming growth factor β/Smad3 pathway by regulating microRNA 140 The lncRNA H19 mediates pulmonary fibrosis by regulating the miR-196a/COL1A1 axis The effect of H19-miR-29b interaction on bleomycin-induced mouse model of idiopathic pulmonary fibrosis Long non-coding RNA H19 defciency ameliorates bleomycin-induced pulmonary infammation and fibrosis miR-489 inhibits silica-induced pulmonary fibrosis by targeting MyD88 and Smad3 and is negatively regulated by lncRNA Long non-coding RNA-ATB promotes EMT during silica-induced pulmonary fibrosis by competitively binding miR-200c lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial-mesenchymal transition by competitively binding miR-141-3p Rbm7 in structural cells: a NEAT way to control fibrosis MiR-503 modulates epithelialmesenchymal transition in silica-induced pulmonary fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1 Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis circRNA mediates silica-induced macrophage activation via HECTD1/ZC3H12A-dependent ubiquitination Silica-induced initiation of circular ZC3H4 RNA/ZC3H4 pathway promotes the pulmonary macrophage activation circHECTD1 promotes the silica-induced pulmonary endothelial-mesenchymal transition via HECTD1 Nongenomic actions of aldosterone and progesterone revisited A network of noncoding regulatory RNAs acts in the mammalian brain An artificially designed interfering lncRNA expressed by oncolytic adenovirus competitively consumes oncomirs to exert antitumor efficacy in hepatocellular carcinoma Long noncoding RNA FENDRR exhibits antifibrotic activity in pulmonary fibrosis Hypoxia and transforming growth factor β1 regulation of long non-coding RNA transcriptomes in human pulmonary fibroblasts Composition-tunable hollow Au/Ag SERS nanoprobes coupled with target-catalyzed hairpin assembly for tripleamplification detection of miRNA The emerging role of lncRNAs in cancer Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy Visualizing RNA dynamics in live cells with bright and stable fluorescent RNAs Long non-coding RNAs: insights into functions Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-β signaling Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation Astaxanthin attenuates pulmonary fibrosis through lncITPF and mitochondria-mediated signal pathways Angelica sinensis polysaccharide suppresses epithelial-mesenchymal transition and pulmonary fibrosis via a DANCR/AUF-1/FOXO3 regulatory axis Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelialmesenchymal transition Astilbin ameliorates pulmonary fibrosis via blockade of hedgehog signaling pathway In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide Long non-coding RNAs: Promising new targets in pulmonary fibrosis